Innovation Portfolio Risk Management

💡 The AI honeymoon is over, and most organizations have little to show for it. After years of pilots, proof-of-concepts, and innovation theater, BCG reports only 26% of companies have deployed working AI products—and a mere 4% see meaningful returns. The problem isn't technology. It's the absence of disciplined strategy married to human purpose. I've spent three decades watching brilliant technologies fail not from technical shortcomings, but from organizational incoherence. AI is no different. What separates companies that generate real value from those burning resources on experiments that go nowhere? Two things: strategic discipline and portfolio thinking. In our recent Harvard Business Review articles, we explore how organizations can move beyond the chaos: First, balance innovation with governance using practical frameworks. Our OPEN and CARE framework provide structured ways to ask the right questions early — questions that align AI with genuine business priorities while protecting against risks that emerge when we automate without thinking. This isn't about slowing down or creating bureaucratic bottlenecks. It's about moving forward with intention, ensuring every AI initiative serves both business value and human purpose. Second, treat AI as a portfolio, not a collection of pet projects. Organizations like Northrop Grumman, PepsiCo, and Lloyds Banking Group have proven that structured portfolio management—complete with prioritization frameworks, resource allocation discipline, and clear buy/sell/hold decisions—transforms AI from cost center to strategic asset. When you combine these approaches, something fundamental shifts. AI stops being something bolted onto strategy and becomes inseparable from it. The result: better returns, less waste, and organizations that remain distinctly human even as they become more technologically capable. The question isn't whether to invest in AI. It's whether you're managing those investments with the same rigor you'd apply to any other strategic portfolio. 🔗 Read further @ 📍 "Two Frameworks for Balancing AI Innovation and Risk" → https://lnkd.in/edHnUzGK 📍 "Manage Your AI Investments Like a Portfolio" [with/ Tom Davenport, Paul Scade, PhD, Erik Nelson] → https://lnkd.in/gEJ_WnyM What's blocking your organization from moving AI from experiments to enterprise value? I'm curious what you're seeing.

Your 'innovative' product strategy might be killing your business. Sounds harsh? Perhaps! But it's a reality many product teams face without realizing it. Some chase after the next big thing while their core offerings suffer. Others play it so safe they become stagnant in a rapidly changing market. There's a better way, and it's all about balance. Our Experiment Type Taxonomy, a framework I've developed in collaboration with Nils Stotz is not  another product strategy – it's a reality check for your innovation and experimentation efforts. Picture your product strategy as an investment portfolio. Just as a savvy investor wouldn't put all their money into high-risk stocks or play it too safe with bonds alone, your product innovation strategy needs a balanced approach. Here's how to slice the pie: 1) A hefty 60-70% chunk for Incremental Optimizations. These are your low-risk and over time steady-return investment and not to forget great sources for learning. 2 + 3) Two modest 10-15% slices for Moderate Restructuring and Feature Additions. Think of these as your balanced funds – potential for significant gains with moderate risk. 4) A final 10-20% slice for Radical Innovations. These are your high-risk, high-reward projects that could lead to breakthrough success. Why this mix? Just like in investing, it's about balancing risk and reward. This approach ensures you're continuously improving your current product while also exploring game-changing innovations. The beauty of this taxonomy is its flexibility. Adjust the slices based on your risk tolerance, funding stage, and resources. But always keep the portfolio balanced. This framework helps you: - Prevent over-focus on "safe" incremental changes at the expense of big ideas - Align experiments with business goals and resources - Support a culture of intentional, strategic experimentation So, take a hard look at your current experiments. Are you managing a well-balanced innovation portfolio, or are you unwittingly exposing yourself to too much risk – or too little? Your product's future might depend on the answer. #ProductStrategy #InnovationBalance #ExperimentationTaxonomy What's your take? Is your innovation portfolio properly diversified? Share your thoughts – or better yet, your pie charts – in the comments!

In a highly regulated and risk-averse environment, the integration of innovation and compliance is crucial. Drawing from experiences with royal commissions and enforced undertakings, I believe that innovation and regulation can coexist harmoniously. Particularly in the realm of payments, a well-crafted risk framework serves as a crucial link between creativity and adherence to regulations, enabling product managers to introduce pioneering solutions while upholding compliance standards. Here are actionable insights on how product leaders can foster innovation while upholding a robust risk management approach: 1️⃣ **Incorporate Risk Early:** Engage compliance and risk teams from the initial stages of ideation. This proactive involvement helps preempt obstacles and cultivates inventive thinking within the regulatory framework. 2️⃣ **Establish Clear Boundaries:** Utilize the risk framework to set explicit parameters for experimentation. These boundaries act as guardrails, ensuring safety while nurturing creativity within defined scopes. 3️⃣ **Iterate Responsively:** Continuously evaluate risks as the product progresses, leveraging input from legal experts, risk professionals, and external regulators to enhance your strategy. A comprehensive risk framework not only addresses compliance concerns but also empowers teams to explore the boundaries of innovation responsibly. How do you leverage risk frameworks to drive innovation within regulated environments? #ProductInnovation #Payments #RiskManagement

Balancing innovation and responsibility under recent AI-related executive order changes requires a deliberate strategy, and #ISO56001 and #ISO42001 provide a structured path to achieve ethical innovation. 1️⃣Align Leadership on Strategy 🧱Why It’s a Challenge: Competing priorities across leadership creates silos, making it difficult to align innovation goals with compliance and ethical considerations. 🪜Solution: Develop a unified strategy that integrates innovation and governance. ISO56001 embeds innovation as a strategic priority, while ISO42001 ensures accountability and ethical AI practices are foundational. ⚙️Action: Form a governance team to align innovation with responsible AI principles and regulatory requirements. 2️⃣Build AI Governance Framework 🧱Why It’s a Challenge: Without governance, innovation will lead to unintended outcomes like bias, regulatory violations, or reputational damage. 🪜Solution: Implement ISO42001 policies to manage AI risks, covering the AI lifecycle from design to deployment. Align governance with your business strategy, and address transparency, bias, and privacy concerns. ⚙️Action: Integrate ISO42001 governance processes into existing ISO56001 innovation frameworks. 3️⃣ Foster a Culture of Responsible Innovation 🧱Why It’s a Challenge: Innovation-focused teams often prioritize speed and creativity over compliance, leading to risks being overlooked. It’s human nature. 🪜Solution: Use ISO56001 to foster innovation capacity while embedding ethical principles from ISO42001. Incentivize responsible AI practices through training and recognition programs. ⚙️Action: Build awareness across teams about the fundamental importance of responsible AI development. 4️⃣Operationalize Risk Management 🧱Why It’s a Challenge: Rapid AI experimentation can outpace the development of controls, exposing your organization to unmitigated risks. 🪜Solution: ISO56001 prioritizes innovation portfolios, while ISO42001 asks for structured risk assessments. Together, they ensure experimentation aligns with governance. ⚙️Action: Establish sandbox environments where AI projects can be tested safely with predefined checks. 5️⃣Establish Continuous Improvement 🧱Why It’s a Challenge: Regulatory environments and AI risks evolve, requiring organizations to adapt their strategies continuously. 🪜Solution: ISO42001 emphasizes monitoring and compliance, while ISO56001 provides tools to evaluate the impact of innovation efforts. ⚙️Action: Create feedback loops to refine innovation and governance, ensuring alignment with strategic and regulatory changes. 6️⃣Communicate Transparency 🧱Why It’s a Challenge: Stakeholders demand evidence of ethical practices, but organizations often lack clarity in communicating AI risks and governance measures. 🪜Solution: Use ISO42001 to define clear reporting mechanisms and ISO56001 to engage stakeholders in the innovation process. ⚙️Action: Publish annual reports showcasing AI governance and innovation efforts.

When uncertainty looms, innovation teams are at risk of being on CFO’s chopping block. Most recently, I joined a half-day roundtable with an outstanding group of corporate innovators, convened by Peter Temes at the ILO Institute during which we tackled this pressing reality and paradox: Companies invest in innovation during good times... but they NEED it most during uncertain ones. This plays out in two ways: 🚫 The First Camp: Slashes innovation budgets at the first sign of trouble. "We’ll restart when things stabilize," they promise. By the time stability returns, competitors have already leapt ahead. 🤦♂️ The Second Camp: Keeps innovation teams intact—but strangles their impact. ROI on experiments must be immediate. Quarterly returns on long-term bets. Zero tolerance for the failures that actually drive learning. I’ve seen both—sometimes inside the same company. The result? Innovation teams lose morale. The best talent disengages—or walks. Stakeholders pull support. A "one-and-done" mindset kills promising ideas before they can grow. 💡 Look at financial services. They came late to the internet, mobility, and social media. Now they’re risking the same mistake with AI, ceding direct customer relationships to fintechs and risking relegation to utility status. Why does this cycle persist? Because the short-term savings of cutting innovation are immediately visible. The long-term catastrophe is invisible... until it's too late. 🔥 Here’s how to keep innovation alive when budgets tighten: 1️⃣ Dramatically lower the cost of individual experiments 2️⃣ Prioritize customer-backed innovation for real-time feedback 3️⃣ Create distributed innovation networks across the org 4️⃣ Speed up cycles by challenging slow status quo processes 5️⃣ Position innovation as risk management, NOT risk-taking ⏳ Don’t let uncertainty kill your company’s future. The best organizations don’t innovate despite uncertainty. They innovate because of it. 🚀 Innovation isn’t a luxury—it’s a lifeline. Julie F., Alex Trotta, Miles Garrett, Andy Grove, Anthony Di Bitonto, Kate Pomeroy (née Stubbs) #innovation #leadership #learning

Every company needs a strategic Portfolio of Initiatives. Leaders need to balance risk/familiarity and time horizon for projects. Sticking to a single strategy is no longer enough. The Portfolio of Initiatives approach, popularized by McKinsey & Company, gives leaders a practical way to manage a mix of short-term gains and long-term growth bets—all while navigating uncertainty. Think in Layers: Risk vs. Familiarity Every initiative your business pursues falls somewhere on this spectrum: Safe & Known – Small upgrades to what already works. Stretch but Achievable – Entering new spaces that are adjacent to your core. Bold & Transformative – High-risk ideas that could redefine your business. Just like a diversified investment portfolio, the goal is to balance risk and reward. Time Matters: Map Across Horizons Each idea unfolds on its own timeline. The framework breaks this down into: Now (0–1 years): Quick wins that boost momentum. Next (1–5 years): Strategic moves that scale over time. Later (5+ years): Big, bold bets that shape the company’s future. Size the Prize: Invest with Purpose Initiatives vary in impact. Think of a visual where the size of each bubble equals its revenue or profit potential. Smart leaders don’t go all in on one type—they spread investments across risk levels, timeframes, and potential returns to drive sustainable success. Bottom Line: The best companies think like great investors—managing a balanced mix of safe bets, growth plays, and future-defining moonshots. How are you shaping your strategic portfolio? Drop your thoughts in the comments—and follow Tim Vipond, FMVA® for more insights on strategy.

🚀 I built an AI Product Risk Management System that unified 14 departments, monitored 58 product segments, protected an $89B portfolio — and transformed how leaders see risk. Most organizations don’t fail because of innovation. They fail because they can’t see the risk inside the innovation. That’s why I built a system that solved what every tech, fintech, and banking company struggles with: 🔹 fragmented data 🔹 slow risk signals 🔹 unclear product segmentation 🔹 reactive fraud response 🔹 escalating regulatory pressure (See page 2 of the carousel — and tell me this isn’t every company’s pain point. 😅) So, I designed an AI-driven, dual-risk rating engine that measures: Inherent Risk + Performance Risk …across product lines, markets, customer segments, and real-time behaviors. The result? A 6-layer AI architecture (data → ML → scoring → alerts → dashboards → governance) that finally gave executives what they never had before: true visibility. (p.4) And the impact was enterprise-wide: ✔ Fraud losses ↓ 30% ✔ Early warnings ↑ by 1.8 months ✔ 600+ hours/year saved ✔ Years-old audit issues closed ✔ Prevented delinquencies & covenant breaches ✔ Unified 14 departments under one intelligence layer ✔ FP&A accuracy skyrocketed with predictive modeling But here’s the bigger insight: AI doesn’t eliminate risk — it eliminates the surprise in risk. (p.10) And eliminating surprise is what unlocks responsible innovation. It’s how Big Tech builds safer AI. It’s how fintech scales without fraud. It’s how banks protect capital and customers. It’s how platforms build trust. (p.8–9) If your organization cares about: ✔ AI governance ✔ Product safety ✔ Fraud + abuse prevention ✔ Predictive risk scoring ✔ Data-driven decision-making ✔ Responsible innovation …then this framework was built for you. 📎 Full carousel PDF posted above. Save it, share it, and send it to an Executive or Senior Leader who needs to see this. If you want a breakdown of the 6-layer system, comment “AI RISK” — Cyn Hutchinson, JD, RAI, CIPM, AIGC Product Risk • AI Governance • Enterprise Strategy #theresponsibleaileaderlady 🔥 #AIProductRisk #ResponsibleInnovation #AIGovernance #ProductManagement #FraudPrevention #RiskLeadership #TechSafety #FintechInnovation #DataGovernance #ExecutiveLeadership #aiblueprint #aiproductrisklady #aileadershiplady #whitepaper #dualriskrating Google JPMorganChase Meta Apple Microsoft Bank of America Amazon Web Services (AWS) Amazon

Pharmaceutical R&D is where billion-dollar dreams go to die. The math is brutal. For every drug that hits the pharmacy shelf, thousands of candidates wither in the lab. The cost of failure isn’t just measured in lost time. It is measured in the $2.6 billion required to bring a single molecule to market. Most portfolios are built on hope rather than hedged risk. This is a fatal strategic error. Concentration risk creates a "cliff" effect. One failed Phase III trial can wipe out a decade of market capitalization overnight. Investors demand growth, but scientific uncertainty creates a ceiling. Relying on a single blockbuster is no longer a viable business model. Navigating this volatility requires a fundamental shift in portfolio architecture. De-risking is the only path to survival. The solution lies in aggressive diversification across therapeutic areas and modalities. Do not put all your capital into oncology or rare diseases. Smart operators balance high-risk, first-in-class assets with lower-risk incremental innovations. They bridge the gap between breakthrough science and steady returns. Utilize predictive analytics to kill failing projects early. Failing fast is the cheapest way to succeed in drug development. Strategic partnerships and out-licensing act as a pressure valve. They spread the financial burden while maintaining a stake in the upside. The goal is a self-sustaining engine. A portfolio that survives the patent cliff because it was built to withstand the descent. In the high-stakes game of pharma R&D, the winner isn't the one with the biggest gamble. It is the one with the best-managed risk. https://lnkd.in/ex5qWcbq #Pharmaceuticals #Patents #Generics